Samuel Saks Insider Profile
4 Followers
Samuel Saks, CMO at Protagonist Therapeutics, holds 14.00K shares in Protagonist Therapeutics (Ticker: PTGX), holds 214.19K shares in PDL BioPharma (Ticker: PDLI), holds 6.61K shares in Tonix Pharma (Ticker: TNXP).
Samuel Saks's Trading History
| PTGXProtagonist Therapeutics | Feb 26, 2021 | CMO | Uninformative Buy | ― | $1.75M | |
| PDLIPDL BioPharma | Jun 12, 2018 | ― | Uninformative Buy | 150.00K | $529.05K | |
| TNXPTonix Pharma | Mar 09, 2018 | Director | Uninformative Buy | 5.44K | $19.02K | |
| ASRTAssertio Therapeutics | May 13, 2016 | ― | Uninformative Sell | 12.86K | $68.08K | |
| ASPXAuspex Pharma | May 05, 2015 | ― | Uninformative Sell | ― | ― | |
| JAZZJazz Pharmaceuticals | ― | CEO, Director | ― | $86.05M |
You May Also Like
Samuel Saks insider profile FAQ
What is the percentage of profitable transactions made by Samuel Saks?
The percentage of profitable transactions made by Samuel Saks is 33%.
What is the average return per transaction made by Samuel Saks?
The average return per transaction made by Samuel Saks is 9.30%.
What stocks does Samuel Saks hold?
Samuel Saks holds: PTGX, ASPX, TNXP, PDLI, ASRT, JAZZ stocks.
What was Samuel Saks's most profitable transaction?
Samuel Saks’s most profitable transaction was an Informative Buy of ASPX stock on February 12, 2014. The return on the trade was 183.70%.
What is Samuel Saks's role in Protagonist Therapeutics?
Samuel Saks's role in Protagonist Therapeutics is CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
